October 21, 2014 5:53 PM ET


Company Overview of Alevium Pharmaceuticals Inc.

Company Overview

Alevium Pharmaceuticals Inc. operates as a biopharmaceutical company. The company specializes in treating poor responders of proton pump inhibitors (PPIs) with acid regulation. Its API 023 is an oral and intravenous PPI for the treatment of gastrointestinal acid-related disorders. The company’s API-023 is a prodrug of omeprazole designed to address significant unmet medical needs in acid-related disorders. Alevium Pharmaceuticals Inc. was incorporated in 2008 and is based in Encinitas, California.

1550 Neptune Avenue

Encinitas, CA 92024

United States

Founded in 2008

Key Executives for Alevium Pharmaceuticals Inc.

Age: 54
Founder and Director
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
WraSer LLC United States
Assura Pharmaceuticals Inc. United States
VivaCeuticals, Inc. United States
Coquí RadioPharmaceuticals, Corp. United States
Nutrition Formulators, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alevium Pharmaceuticals Inc., please visit www.alevium.ca. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.